Welcome to our dedicated page for Hemab Therapeutics Holdings news (Ticker: COAG), a resource for investors and traders seeking the latest updates and insights on Hemab Therapeutics Holdings stock.
Hemab Therapeutics Holdings reports corporate and clinical-stage biotechnology developments tied to its blood coagulation disorder programs. Company news includes its Nasdaq listing and initial public offering, capital-structure updates, shareholder voting matters, and clinical or regulatory disclosures related to rare bleeding disorder therapeutics.
Updates for COAG also center on Hemab's development focus, including sutacimig (HMB-001), a bispecific antibody program for prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency.
Hemab Therapeutics (COAG) has dosed the first healthy volunteer in its Phase 1 clinical trial of HMB-003, an investigational therapy being developed for the management of heavy menstrual bleeding (HMB).
HMB-003 is described as a novel fatty-acid-conjugated peptide antifibrinolytic designed to stabilize clots by directly inhibiting plasmin at its active site, blocking fibrinolysis independently of the plasminogen activation pathway. In preclinical models, HMB-003 showed greater activity than tranexamic acid, and in minipigs a single subcutaneous dose produced peak plasma levels within hours with antifibrinolytic activity lasting about one week, supporting the potential for cycle-matched, once-per-cycle dosing.
The randomized, placebo-controlled, single-ascending-dose Phase 1 study (NCT07798505) will assess safety, tolerability, pharmacokinetics and pharmacodynamics in healthy adults and is expected to guide dose selection and development plans for HMB-003 in HMB and other high-unmet-need bleeding conditions. Hemab expects to share data from this study no later than mid-2027.
The Galien Foundation announced the 2026 Prix Galien USA nominees for four categories: Best Digital Health Solution, Best Medical Technology, Incubators, Accelerators and Equity, and Best Startup. Winners will be honored on October 29, 2026, at the American Museum of Natural History in New York City.
Nominees span leading global companies, funds, academic accelerators and startups, including Hemab Therapeutics (Nasdaq: COAG) in the Best Startup category. According to The Galien Foundation, candidates are evaluated on scientific excellence and potential health impact; for Best Medical Technology, products must have received FDA marketing approval within the last five years.
The Galien Foundation issued a corrected announcement naming the 2026 Prix Galien USA nominees for four categories: Best Digital Health Solution, Best Medical Technology, Incubators, Accelerators and Equity, and Best Startup. Winners will be honored on October 29, 2026 at the American Museum of Natural History in New York City.
The update specifies that Future Doctor Inc has been added to the Best Digital Health Solution nominees for its MedGPT – AI Digital Twin of Doctors. The release also highlights the award criteria, global reach of the Prix Galien, and the high-profile 2026 awards committee.
Hemab Therapeutics (Nasdaq: COAG) reported second quarter 2026 results and substantial pipeline progress in bleeding disorders. Cash, cash equivalents and marketable securities were $457.5 million at June 30, 2026, boosted by $317.2 million in IPO net proceeds, providing a cash runway into 2029. Q2 2026 R&D expenses were $20.3 million and G&A expenses were $5.7 million, leading to a net loss of $24.2 million or $0.80 per share.
At ISTH 2026, sutacimig Phase 2 LTE data in Glanzmann thrombasthenia showed a 62% mean reduction in high-intensity annualized treated bleed rate (ATBR) in 34 participants and around 84% reduction in a low-dose weekly cohort. FDA endorsed the sutacimig package to proceed to a Phase 3 GT trial, planned to start in 2H 2026. First‑in‑human HMB‑002 data in Von Willebrand disease showed ≥2.4‑fold peak increases in VWF and FVIII and a drop in mean ATBR from 20.1 at baseline to 1.6, with 8 of 9 evaluable patients having zero treated bleeds in the 28 days post‑dose. Hemab also unveiled HMB‑003, a long‑acting subcutaneous plasmin inhibitor for heavy menstrual bleeding and other indications, with first‑in‑human studies planned for 2H 2026.
Hemab Therapeutics (Nasdaq: COAG) reported new clinical and preclinical data for sutacimig in Glanzmann thrombasthenia (GT) and Factor VII deficiency (FVIID) at the ISTH 2026 Congress. Phase 2 long-term extension (LTE) data in GT, covering 34 patients with a median 6.9 months and up to 15.9 months of exposure, showed sustained prophylactic bleed reduction and a manageable safety and tolerability profile. FDA has endorsed proceeding to a Phase 3 trial in 2H 2026 with a 0.2 mg/kg weekly regimen.
According to Hemab, 92% of participants who bled during run-in had reduced treated bleed rates on sutacimig, high‑intensity treated bleeds fell by 62%, and the low-dose weekly cohort saw about an 84% reduction in mean annualized treated bleeding rate. Three surgical or procedural cases achieved successful hemostasis. Adverse events were mostly mild or moderate, with three Grade 2 thromboembolic events in higher‑exposure or high‑risk cohorts, all managed with routine anticoagulation. Preclinical FVIID data showed restoration of thrombin generation and binding to most tested variants. Natural history studies (GT360, ATHN Transcends) documented lifelong weekly bleeding, high depressive symptom rates, and low prophylaxis use, reinforcing unmet need.
Hemab Therapeutics (Nasdaq: COAG) reported new first-in-human data for HMB-002 in Von Willebrand disease (VWD) and introduced HMB-003 for heavy menstrual bleeding at the ISTH 2026 Congress. HMB-002 showed dose-dependent ≥2.4-fold peak increases in Von Willebrand factor (VWF) and Factor VIII (FVIII), normalization of peak thrombin generation and activated partial thromboplastin time (APTT), and a pharmacokinetic/pharmacodynamic profile supporting potential monthly subcutaneous dosing.
According to Hemab, most treatment-emergent adverse events were mild or moderate, with no serious events, discontinuations, or thromboembolic, injection site, thrombocytopenia or hypersensitivity events. In the single ascending dose cohorts, 8 of 9 evaluable patients had zero treated bleeds over 28 days, versus a baseline mean annualized treated bleed rate of 20.1. Hemab also announced HMB-003, a non-hormonal, fatty-acid-conjugated peptide antifibrinolytic that directly inhibits plasmin, showed potent, selective antifibrinolytic activity and approximately one-week duration after a single subcutaneous dose in minipigs, supporting potential cycle-matched dosing in heavy menstrual bleeding.
Hemab Therapeutics (Nasdaq:COAG) will present nine clinical and preclinical updates from its coagulation pipeline at the ISTH 2026 Congress in Paris on July 11-15, 2026.
Highlights include Phase 2 LTE sutacimig data in GT, first-in-human HMB-002 results in VWD, and preclinical HMB-003 antifibrinolytic data.
Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotech focused on blood coagulation disorders, will participate in the 2026 Jefferies Global Healthcare Conference in New York.
A fireside chat is scheduled for Thursday, June 4, 2026 at 9:20 AM ET, with a live webcast and replay available on Hemab’s investor website.
Hemab Therapeutics (Nasdaq:COAG) reported Q1 2026 results and outlined clinical and financing milestones.
The company completed an upsized IPO in May 2026, raising $346.7 million gross, received FDA Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia, advanced multiple trials, and ended Q1 with $163.5 million in cash and securities.
Hemab Therapeutics (Nasdaq: COAG) closed its upsized initial public offering on May 4, 2026, selling 19,262,500 shares at $18.00 per share, including 2,512,500 shares from full exercise of the underwriters' option. Gross proceeds were approximately $346.7 million.
The company’s common stock began trading on the Nasdaq Global Select Market on May 1, 2026 under ticker COAG. A registration statement was declared effective April 30, 2026.